Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves survival, but options for patients intolerant of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-10-01
|
| Series: | Diseases |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2079-9721/3/4/306 |